Literature DB >> 22981610

Patterns of regional recurrence after curative D2 resection for stage III (N3) gastric cancer: implications for postoperative radiotherapy.

Jee Suk Chang1, Joon Seok Lim, Sung Hoon Noh, Woo Jin Hyung, Ji Yeong An, Yong Chan Lee, Sun Young Rha, Chang Geol Lee, Woong Sub Koom.   

Abstract

BACKGROUND AND
PURPOSE: To analyze patterns of regional recurrence after curative gastrectomy and D2 lymph node dissection in patients with stage III (N3) gastric cancer.
MATERIALS AND METHODS: Between 2004 and 2008, 2918 patients with primary gastric cancer underwent D2 resection at a single institution. A retrospective review was performed on 382 patients in stage III with N3 disease. Of these, 357 patients (93.5%) received adjuvant chemotherapy. None of the patients received pre- or postoperative radiotherapy.
RESULTS: Median follow-up was 56.3 months. The 5-year regional failure free-survival (RFFS) rate was 63.6%. Regional failure (RF) as any component of first recurrence occurred in 91 patients (23.8%), with isolated regional failure occurring in 49 (12.8%). The most commonly involved lymph nodes were the No. 16b, No. 16a, No. 12, No. 14, No. 13, and No. 9 nodes. RFFS was adversely affected by advanced nodal stage (N3b vs. N3a). The 5-year progression-free survival rate was 32.1% and overall survival was 41.5%.
CONCLUSION: The most prevalent nodal recurrence in patients with advanced gastric cancer was in the nodal basin outside the D2 dissection field. Our findings may help physicians construct a lymph node target volume for radiation treatment of gastric cancer after D2 dissection.
Copyright © 2012 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22981610     DOI: 10.1016/j.radonc.2012.08.017

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  22 in total

1.  Postoperative follow-up programs improve survival in curatively resected gastric and junctional cancer patients: a propensity score matched analysis.

Authors:  Leila Sisic; Moritz J Strowitzki; Susanne Blank; Henrik Nienhueser; Sara Dorr; Georg Martin Haag; Dirk Jäger; Katja Ott; Markus W Büchler; Alexis Ulrich; Thomas Schmidt
Journal:  Gastric Cancer       Date:  2017-07-24       Impact factor: 7.370

2.  Survival outcomes and patterns of failure after D2 dissection and adjuvant chemoradiotherapy for locally advanced gastric cancer: a retrospective study.

Authors:  Wang Yang; Ran Hu; Gui-Chao Li; Meng-Long Zhou; Yan Wang; Li-Jun Shen; Li-Ping Liang; Zhen Zhang
Journal:  Br J Radiol       Date:  2018-07-27       Impact factor: 3.039

3.  Mapping patterns of nodal metastases in esophageal carcinoma: rethinking the clinical target volume for supraclavicular nodal irradiation.

Authors:  Yijun Luo; Yuhui Liu; Xiaoli Wang; Bin Zhang; Jinming Yu; Chengang Wang; Yong Huang; Minghuan Li
Journal:  J Thorac Dis       Date:  2016-11       Impact factor: 2.895

Review 4.  Postoperative adjuvant chemoradiotherapy in D2-dissected gastric cancer: is radiotherapy necessary after D2-dissection?

Authors:  Jee Suk Chang; Woong Sub Koom; Youngin Lee; Hong In Yoon; Hyung Sik Lee
Journal:  World J Gastroenterol       Date:  2014-09-28       Impact factor: 5.742

5.  Integration of radiotherapy and chemotherapy for abdominal lymph node recurrence in gastric cancer.

Authors:  J Lee; H I Yoon; S Y Rha; W J Hyung; Y C Lee; J S Lim; H S Kim; W S Koom
Journal:  Clin Transl Oncol       Date:  2017-05-05       Impact factor: 3.405

6.  A phase II trial of concurrent 3D-CRT/IMRT and oxaliplatin, 5-fluorouracil and leucovorin (FOLFOX) in gastric cancer patients with R0 gastrectomy and D2 lymph node dissection.

Authors:  Xin Wang; Yali Shen; Hong Zhu; Yaqin Zhao; Zhiping Li; Meng Qiu; Qiu Li; Hongfeng Gou; Yu Yang; Dan Cao; Jiyan Liu; Cheng Yi; Zhengyin Liao; Deyun Luo; Feng Bi; Feng Xu
Journal:  Gastric Cancer       Date:  2015-01-22       Impact factor: 7.370

7.  Adjuvant chemoradiotherapy versus adjuvant chemotherapy for R1 resected gastric cancer: a retrospective cohort study.

Authors:  Meng-Long Zhou; Gui-Chao Li; Wang Yang; Wei-Juan Deng; Ran Hu; Yan Wang; Zi-Wen Long; Xiao-Wen Liu; Ya-Nong Wang; Zhen Zhang
Journal:  Br J Radiol       Date:  2018-06-27       Impact factor: 3.039

Review 8.  Current adjuvant treatment modalities for gastric cancer: From history to the future.

Authors:  Leyla Kilic; Cetin Ordu; Ibrahim Yildiz; Fatma Sen; Serkan Keskin; Rumeysa Ciftci; Kezban Nur Pilanci
Journal:  World J Gastrointest Oncol       Date:  2016-05-15

9.  Chemoradiotherapy or chemotherapy as adjuvant treatment for resected gastric cancer: should we use selection criteria?

Authors:  Houyem Mansouri; Ines Zemni; Leila Achouri; Najet Mahjoub; Mohamed Ali Ayedi; Ines Ben Safta; Tarek Ben Dhiab; Riadh Chargui; Khaled Rahal
Journal:  Rep Pract Oncol Radiother       Date:  2021-04-14

10.  Postoperative adjuvant radiotherapy for patients with gastric adenocarcinoma.

Authors:  Do Hoon Lim
Journal:  J Gastric Cancer       Date:  2012-12-31       Impact factor: 3.720

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.